2-ethyl-L-tyrosine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-ethyl-L-tyrosine
• 英文别名: (2S)-2-amino-3-(2-ethyl-4-hydroxyphenyl)propanoic acid
• 化学式: C₁₁H₁₅NO₃
• 分子量: 209.245
• InChiKey: BOLUZPBFHZSEQD-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  9-芴甲基-N-琥珀酰亚胺基碳酸酯 、 2-ethyl-L-tyrosine 在 sodium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 生成
  参考文献：
  名称：

  Tyrosine analogues as alternative substrates for protein tyrosine kinase Csk: Insights into substrate selectivity and catalytic mechanism

  摘要：

  Protein tyrosine kinases are critical enzymes in cell signal transduction but relatively little is known about the molecular recognition of the tyrosine substrate by these enzymes. Details of tyrosine substrate specificity within the context of a short peptide were investigated for protein tyrosine kinase Csk. It was found that aryl ring functional group substitutions the size of methyl group or smaller were generally well tolerated by the protein tyrosine kinase Csk whereas larger groups caused a decline in substrate efficiency. Extension of the phenol from the peptide backbone by a single methylene was acceptable for phosphorylation whereas removal of a methylene nearly abolished reactivity. Only the L-tyrosine derivative was processed. A negative charge ortho to the phenol hydroxyl was incompatible with substrate reactivity, consistent with previous pH rate profiles which indicated the importance of the neutral phenol. Overall, these studies confirmed the interpretation of a previous linear free energy relationship analysis which suggested that the enzyme followed a dissociative transition state mechanism. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00053-5
• 作为产物：
  描述：

  3-乙基苯酚 、 丙酮酸 在 tyrosine phenol-lyase 、 氨 作用下， 生成 2-ethyl-L-tyrosine
  参考文献：
  名称：

  Tyrosine analogues as alternative substrates for protein tyrosine kinase Csk: Insights into substrate selectivity and catalytic mechanism

  摘要：

  Protein tyrosine kinases are critical enzymes in cell signal transduction but relatively little is known about the molecular recognition of the tyrosine substrate by these enzymes. Details of tyrosine substrate specificity within the context of a short peptide were investigated for protein tyrosine kinase Csk. It was found that aryl ring functional group substitutions the size of methyl group or smaller were generally well tolerated by the protein tyrosine kinase Csk whereas larger groups caused a decline in substrate efficiency. Extension of the phenol from the peptide backbone by a single methylene was acceptable for phosphorylation whereas removal of a methylene nearly abolished reactivity. Only the L-tyrosine derivative was processed. A negative charge ortho to the phenol hydroxyl was incompatible with substrate reactivity, consistent with previous pH rate profiles which indicated the importance of the neutral phenol. Overall, these studies confirmed the interpretation of a previous linear free energy relationship analysis which suggested that the enzyme followed a dissociative transition state mechanism. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00053-5

文献信息

• Diagnostic and therapeutic agents
  申请人：Taube Seija

  公开号：US20070258899A1

  公开（公告）日：2007-11-08

  Tumor targeting units are disclosed which have a peptide sequence C y —Y—G-F—X—W-G-Z-C yy (SEQ ID NO: 25), or a pharmaceutically or physiologically acceptable salt thereof. Tumor targeting agents are also disclosed having at least one targeting unit, directly or indirectly coupled to at least one effector unit. Diagnostic or pharmaceutical compositions having at least one targeting unit or at least one targeting agent, and targeting units or targeting agents for the preparation of a medicament for the treatment of cancer related diseases (including cancer), especially for the treatment of colon/colorectal cancer or its metastases are also disclosed.

  揭示了具有肽序列Cy—Y—G-F—X—W-G-Z-Cyy（序列ID编号：25）或其药学或生理上可接受的盐的肿瘤靶向单元。还披露了具有至少一个靶向单元的肿瘤靶向剂，直接或间接地偶联至至少一个效应单元。还披露了具有至少一个靶向单元或至少一个靶向剂的诊断或药物组合物，以及用于制备治疗癌症相关疾病（包括癌症）的药物的靶向单元或靶向剂，特别是用于治疗结肠/结直肠癌或其转移的靶向单元或靶向剂。
• NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION
  申请人：Barlow Carrolee

  公开号：US20070049576A1

  公开（公告）日：2007-03-01

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  该即时披露描述了通过刺激或增加神经发生来治疗中枢神经系统和外周神经系统的疾病和病症的方法。该披露包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经生成剂结合以刺激或激活新神经细胞的形成。
• Antagonists of the antidiuretic action of arginine vasopressin
  申请人：Medical College of Ohio

  公开号：EP0115379A2

  公开（公告）日：1984-08-08

  Compounds which may be used as antagonists of the antidiuretic action of arginine vasopression have the formula: in which: X is (D- or L-)Tyr(R) (in which R is methyl, ethyl, propyl or butyl), D-Tyr, D-Phe, D-Val, D-Leu, D-Ile, D-Arg, D-Gln, D-Asn, D-NVa, D-Nle, D-Cha, D-Abu, D-Thr or D-Met; Y is (D- or L-)Cys; W is (D- or L-)Pro, Δ3-Pro, or HO-Pro; Z is (D- or L-)Arg, (D- or L-)Lys or (D- or L-)Orn; and n is 4 or 5; provided that when X is other than D-Gln or D-Arg, W is Pro, Y is Cys and Z is (D- or L-)Arg, n is 4; and when X is (D- or L-)Tyr(R) and n is 5, W is HO-Pro or D-Pro.

  可用作精氨酸血管紧张素抗利尿作用拮抗剂的化合物具有以下式子： 其中： X 是(D-或 L-)Tyr(R)（其中 R 是甲基、乙基、丙基或丁基）、D-Tyr、D-Phe、D-Val、D-Leu、D-Ile、D-Arg、D-Gln、D-Asn、D-NVa、D-Nle、D-Cha、D-Abu、D-Thr 或 D-Met；Y 是(D-或 L-)Cys；W 是(D-或 L-)Pro、Δ3-Pro 或 HO-Pro； Z是(D-或L-)Arg、(D-或L-)Lys或(D-或L-)Orn；n是4或5；但当X不是D-Gln或D-Arg时，W是Pro，Y是Cys，Z是(D-或L-)Arg，n是4；当X是(D-或L-)Tyr(R)，n是5时，W是HO-Pro或D-Pro。
• Arginine vasopressin antagonists
  申请人：Medical College of Ohio

  公开号：EP0151016A2

  公开（公告）日：1985-08-07

  Arginine vasopressin antagonists have the formula:1. in which: Y is Va, lle, Thr, Ala, Lys, Cha, Nva, Met, Nle, Orn, Ser, Asn, Gin, Phe, Tyr, Gly, Abu or Leu; X is (D- or L-) Tyr (R) (in which R is methyl, ethyl, butyl or propyl or, when Y is Val or Gln, H), or D-Phe, D-Val, D-Leu, D-lle, D-Nva, D-Nle, D-Cha, D-Abu, D-Thr, D-Asn, D-Gln or D-Met; Z is (D- or L-)Arg, Orn or Lys; Q is Arg(NH2), Ser(NH2), (D-or L-) Ala(NH2), Gly, OH or NH; and 2 n is 4 or 5.

  精氨酸加压素拮抗剂的化学式为：1. 其中Y是Va、le、Thr、Ala、Lys、Cha、Nva、Met、Nle、Orn、Ser、Asn、Gin、Phe、Tyr、Gly、Abu或Leu； X 是（D-或 L-）Tyr（R）（其中 R 是甲基、乙基、丁基或丙基，或当 Y 是 Val 或 Gln 时，是 H），或 D-Phe、D-Val、D-Leu、D-lle、D-Nva、D-Nle、D-Cha、D-Abu、D-Thr、D-Asn、D-Gln 或 D-Met； Z 是（D-或 L-）Arg、Orn 或 Lys； Q 是 Arg(NH2)、Ser(NH2)、(D-或 L-)Ala(NH2)、Gly、OH 或 NH；和 2 n 是 4 或 5。
• Derivatives of arginine vasopressin antagonists
  申请人：Medical College of Ohio

  公开号：EP0189326A2

  公开（公告）日：1986-07-30

  Compounds acting as antagonists of the antidiuretic/ and or vasopressor activity of arginine vasopressin have the formula wherein n is 4 or 5; X is (D- or L-)Tyr (R), (in which R is C1-C4 alkyl, D-Phe, D-Val, D-Leu, D-Ile, D-Nva, D-Nle, D-Cha, D-Abu, D-Thr, D-Asn, D-Gln or D-Met; Y is Val, Ile, Thr, Ala, Lys, Cha, Nva, Met, Nle, Orn, Ser, Asn, Gin, Phe, Tyr, Gly, Abu or Leu; Z is (D-or L-)Arg, Orn or Lys; and Q is Orn(NH2), NHCH2CH2NH2 Val(NH2), Phe(NH2), Ile(NH2), Thr(NH2), Pro(NH2) or Tyr(NH2), provided that when Y is Val or Gin, R is also H.

  作为精氨酸血管加压素的抗利尿活性/和或血管加压活性拮抗剂的化合物具有以下式子 其中 n 是 4 或 5；X 是 (D- 或 L-)Tyr (R)，（其中 R 是 C1-C4 烷基、D-Phe、D-Val、D-Leu、D-Ile、D-Nva、D-Nle、D-Cha、D-Abu、D-Thr、D-Asn、D-Gln 或 D-Met；Y 是 Val、Ile、Thr、Ala、Lys、Cha、Nva、Met、Nle、Orn、Ser、Asn、Gin、Phe、Tyr、Gly、Abu 或 Leu；Z 是 (D-或 L-)Arg、Orn 或 Lys；Q 是 Orn(NH2)、NHCH2CH2NH2 Val(NH2)、Phe(NH2)、Ile(NH2)、Thr(NH2)、Pro(NH2) 或 Tyr(NH2)，但当 Y 是 Val 或 Gin 时，R 也是 H。